Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 0 | 0 | 2,101 | 2,481 | 3,534 |
| Cost of Goods | N/A | N/A | 1,018 | 819 | 1,795 |
| Gross Profit | N/A | N/A | 1,083 | 1,662 | 1,739 |
| Operating Expenses | 1,617 | 2,291 | 2,109 | 3,179 | 3,585 |
| Operating Income | -1,617 | -2,291 | -1,008 | -698 | -1,051 |
| Other Income | -532 | -634 | -711 | -655 | -677 |
| Pre-tax Income | -2,149 | -2,925 | -1,719 | -1,353 | -1,728 |
| Net Income Continuous | -2,149 | -2,925 | -1,719 | -1,353 | -1,728 |
| Net Income Discontinuous | 564 | -289 | -2,389 | -404 | -308 |
| Net Income | $-1,585 | $-3,214 | $-4,108 | $-1,757 | $-2,036 |
| EPS Basic Total Ops | -1.37 | -29.95 | -51.88 | -13.11 | -44.43 |
| EPS Basic Continuous Ops | -1.86 | -27.54 | -35.77 | -10.10 | -41.04 |
| EPS Basic Discontinuous Ops | 0.49 | -2.41 | -15.95 | -3.01 | -3.39 |
| EPS Diluted Total Ops | -1.37 | -29.95 | -51.88 | -13.11 | -44.43 |
| EPS Diluted Continuous Ops | -1.86 | -27.54 | -35.77 | -10.10 | -41.04 |
| EPS Diluted Discontinuous Ops | 0.49 | -2.41 | -15.95 | -3.01 | -3.39 |
| EPS Diluted Before Non-Recurring Items | -1.37 | -4.90 | -33.22 | N/A | N/A |
| EBITDA(a) | $-1,611 | $-2,279 | $-996 | $-685 | $-1,038 |